Active ingredientVoxelotorCat. No. P-V066-001CAS 1446321-46-5Family · Pharmaceutical analytical standards
Voxelotor
An oral medicine for sickle cell disease that acts directly on haemoglobin. Approved in the United States in 2019 and in the European Union in 2022, it was withdrawn from the market in 2024. This family brings together the active ingredient and labelled standards.
Did you know?It was the first haemoglobin oxygen-affinity modulator: by keeping haemoglobin S bound to oxygen, it slows the polymerisation that bends red blood cells into a sickle shape.
Go to the active ingredient →Active ingredientVoxelotorCat. No. P-V066-001CAS 1446321-46-5
Isotopically labelledVoxelotor-d6Cat. No. P-V066-002No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.